For the quarter ended March 2025, Veralto (VLTO) reported revenue of $1.33 billion, up 6.9% over the same period last year. EPS came in at $0.95, compared to $0.84 in the year-ago quarter. The reported revenue represents a surprise of +3.79% over the Zacks Consensus Estimate of $1.28 billion. With the consensus EPS estimate being $0.87, the EPS surprise was +9.20%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their nex ...

Markel Group (MKL) reported $3.55 billion in revenue for the quarter ended March 2025, representing a year- over-year decline of 0.5%. EPS of $25.72 for the same period compares to $18.17 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $3.55 billion, representing a surprise of -0.01%. The company delivered an EPS surprise of +36.16%, with the consensus EPS estimate being $18.89. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- a ...

Bausch Health (BHC) reported $2.26 billion in revenue for the quarter ended March 2025, representing a year- over-year increase of 4.9%. EPS of $0.59 for the same period compares to $0.59 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $2.27 billion, representing a surprise of -0.54%. The company delivered an EPS surprise of -28.92%, with the consensus EPS estimate being $0.83. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall ...

Allstate (ALL) reported $16.8 billion in revenue for the quarter ended March 2025, representing a year-over- year increase of 8.9%. EPS of $3.53 for the same period compares to $5.13 a year ago. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. Shares of Allstate have returned -4.2% over the past month versus the Zacks S& ...

Core Viewpoint - OBI Pharma has received FDA clearance for the investigational new drug application of OBI-902, a novel Trop-2 targeted antibody-drug conjugate, marking a significant milestone in the development of a potentially best-in-class cancer therapy for patients with advanced solid tumors [1][2][5]. Group 1: OBI-902 Overview - OBI-902 is a Trop-2-targeted antibody-drug conjugate utilizing OBI's proprietary GlycOBI technology, designed to enhance therapeutic index and stability [3][4]. - The drug carries a potent topoisomerase I inhibitor payload with a drug-antibody ratio (DAR) of 4, targeting various solid tumors such as breast, ovarian, and gastric cancers [4][5]. - The Phase 1/2 clinical study for OBI-902 is set to begin patient enrollment in the second half of 2025 [2][5]. Group 2: Clinical Trial and Efficacy - The upcoming OBI-902-001 clinical trial aims to evaluate the safety, pharmacokinetics, and preliminary efficacy of OBI-902 in patients with advanced solid tumors [2]. - Data presented at the 2025 American Association for Cancer Research (AACR) meeting indicated enhanced linker-payload stability and superior antitumor activities of OBI-902 compared to other Trop-2 ADCs in various in-vitro and animal studies [2][5]. Group 3: GlycOBI Technology - OBI's GlycOBI platform allows for the creation of site-specific glycan-conjugated ADCs, improving stability and hydrophilicity while maintaining the biophysical characteristics of native antibodies [7]. - The technology utilizes proprietary enzymatic and linker technologies to generate homogeneous ADCs with efficient and scalable manufacturing processes [7]. Group 4: Company Background - OBI Pharma, established in 2002 and headquartered in Taiwan, focuses on developing novel cancer therapeutic agents for patients with high unmet medical needs [8]. - The company holds exclusive worldwide rights to the Trop-2 targeting antibody licensed from Biosion, Inc., except for rights pertaining to the antibody in China [6].

In Brief Epic Games notched a win in an ongoing legal dispute with Apple. The result could be Fortnite returning to the U.S. iOS app store as early as next week. Judge Yvonne Gonzalez Rogers said in a ruling Wednesday that Apple was in "willful violation" of a 2021 injunction that prohibited the company from anticompetitive pricing. Exhibit at TechCrunch Sessions: AI Apple won many of the arguments in the Epic Games trial. One notable exception was a ruling that prohibited Apple from collecting fees on purc ...

Core Viewpoint - Despite missing Q1 earnings expectations, Spotify's stock has risen over 3% since the report, outperforming broader market declines and even surpassing Netflix's stock performance year-to-date [1] Group 1: Q1 Results - Spotify reported Q1 EPS of $1.13, missing expectations of $2.29, but showing a 7% increase from $1.05 in Q1 2024 [2] - Q1 sales rose 11% year-over-year to $4.4 billion, although this was below the estimated $4.59 billion [2] Group 2: Subscriber Growth - Spotify's net subscribers increased by 12% in Q1, reaching 268 million, with 5 million new net subscribers added [3] - Monthly active users (MAU) grew by 3 million to 678 million [3] Group 3: Guidance & Outlook - For Q2, Spotify expects to add 11 million MAU and 5 million subscribers, forecasting revenue of $4.52 billion, reflecting a 10% growth [4] - Total sales are projected to increase by 16% in fiscal 2025 and another 15% in FY26, reaching $22.55 billion [4] Group 4: Margin Expectations - Spotify anticipates improvement in full-year margins for 2025, albeit at a more measured pace compared to last year's exceptional gains [5] Group 5: Earnings Estimates - Earnings estimate revisions have trended higher, with FY25 and FY26 EPS estimates up 5% and 8% respectively over the last 60 days [8] - Annual earnings are expected to increase by 78% this year to $10.61 per share, up from $5.95 in 2024, with FY26 EPS projected to rise by 31% to $13.95 [8] Group 6: Investment Sentiment - Spotify's rapid expansion and positive earnings estimate revisions have led to a Zacks Rank 1 (Strong Buy), suggesting continued strong stock performance [9]

Core Points - Canadian Solar Inc. filed its annual report on Form 20-F for the year ended December 31, 2024, with the U.S. SEC [1] - The annual report is accessible on the Company's Investor Relations website and the SEC's website [1] Company Overview - Canadian Solar is one of the largest solar technology and renewable energy companies globally, founded in 2001 and headquartered in Kitchener, Ontario [2] - The Company is a leading manufacturer of solar photovoltaic modules and provides solar energy and battery energy storage solutions [2] - Canadian Solar has delivered nearly 150 GW of solar photovoltaic modules worldwide over the past 24 years [2] - The subsidiary e-STORAGE has shipped over 10 GWh of battery energy storage solutions, with a contracted backlog of US$3.2 billion as of December 31, 2024 [2] - Since entering project development in 2010, Canadian Solar has developed approximately 11.5 GWp of solar power projects and 4.5 GWh of battery energy storage projects globally [2] - The Company has a diversified project development pipeline, including 25 GWp of solar and 75 GWh of battery energy storage capacity in various stages of development [2] - Canadian Solar is recognized as one of the most bankable companies in the solar and renewable energy industry and has been publicly listed on NASDAQ since 2006 [2]

TULSA, Okla., April 30, 2025 /PRNewswire/ -- AAON, INC. (NASDAQ-AAON), a leader in high-performing, energy- efficient HVAC solutions that bring long-term value to customers and owners, today announced its results for the first quarter of 2025. Gary Fields, CEO, stated, "We had a strong first quarter. Net sales, gross margin and earnings all experienced quarter-over- quarter improvement. Production of BASX-branded equipment made solid progress as we accelerated backlog conversion, utilizing all four of our m ...

Core Viewpoint - Bausch Health (BHC) reported quarterly earnings of $0.59 per share, missing the Zacks Consensus Estimate of $0.83 per share, indicating an earnings surprise of -28.92% [1] Financial Performance - The company posted revenues of $2.26 billion for the quarter ended March 2025, which was below the Zacks Consensus Estimate by 0.54%, compared to revenues of $2.15 billion a year ago [2] - Over the last four quarters, Bausch has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Bausch shares have declined approximately 31.6% since the beginning of the year, contrasting with the S&P 500's decline of -5.5% [3] - The current Zacks Rank for Bausch is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $1.05 on revenues of $2.46 billion, and for the current fiscal year, it is $4.26 on revenues of $9.92 billion [7] - The estimate revisions trend for Bausch is mixed, and changes in estimates for the coming quarters and current fiscal year are anticipated following the recent earnings report [6][7] Industry Context - The Medical - Generic Drugs industry, to which Bausch belongs, is currently in the top 20% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8]